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ORIGINAL ARTICLE
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Background: Localized early-stage extra-nodal marginal zone lymphoma (MZL) presents with heterogeneous organ involvement and is treated with various modalities, including resection, radiotherapy, and systemic therapy. We report the long-term
outcome of a large cohort of extra-nodal MZL and assess the impact of patient and disease characteristics, organ site, and
treatment strategy on disease control and survival.
Patients and methods: We identified 487 consecutive patients with stage IE or IIE MZL referred between 1992 and 2012 to
Memorial Sloan Kettering Cancer Center. Pathology was reviewed by hematopathologists at our institution. Patient and
disease factors as well as treatment types were analyzed for association with relapse-free survival, overall survival, and cumulative incidence of relapse.
Results: Median follow-up after treatment was 4.7 years. Five-year relapse-free survival and overall survival were 60% and 89%,
respectively. Cumulative incidence of disease-specific death at 5 years was 1.3%. Radiotherapy alone was the initial treatment
in 50% of patients, followed by surgical resection (30%), observation (8%), immunotherapy (4%), and chemotherapy (2%). Initial
treatment type, primary disease site, and number of involved sites were significant factors in multivariable analysis of relapse
(all P < 0.05). When compared with stomach, MZL originating in other disease sites (HR > 2.0, P  0.001), except for thyroid,
had higher risk of relapse. Strategies such as antibiotics or topical therapies were associated with higher risk of relapse when
compared with radiation therapy (P < 0.001). Crude rate of transformation to pathologically confirmed large-cell lymphoma
was 2% (11 patients).
Conclusion: Overall and cause-specific survival are high in early-stage extra-nodal MZL. Curative-intent treatment led to fewer
relapses and reduced the need for salvage. Stomach cases had lower risk of relapse than other anatomic primary sites. This
study supports the use of local therapies to treat stage IE and IIE MZL.
Key words: marginal zone lymphoma, outcomes, extranodal, early stage

Introduction
Extra-nodal mucosa-associated lymphoid tissue (MALT) lymphoma represents 70% of marginal zone B-cell lymphomas
(MZL) while splenic and nodal sites make up the remaining 30%
of cases [1]. Extra-nodal MZL presents in a variety of organs,

such as the stomach, orbital adnexa, salivary glands, and lungs,
among other sites. Extra-nodal MZL has been linked with two
main bacterial infections: Helicobacter pylori infection in gastric
MZL and Chlamydia psittaci in orbital tissues, with geographic
variation in frequencies [1]. Treatment of H. pylori leads to
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regression of lymphoma in many gastric cases. In other sites,
chronic autoimmune or inflammatory conditions are associated
with development of MZL, such as Sjogren syndrome in salivary
glands and Hashimoto thyroiditis in the thyroid.
Extra-nodal MZL is typically diagnosed at an early, localized
stage in 60%–80% of cases [2, 3], making local treatments the
preferred initial treatment approach. However, the treatment
regimens used in practice are variable, with some patients receiving systemic therapy despite staging workup that confirms the
localized nature of disease. Recent analysis of the National
Cancer Database shows a survival detriment to omission of radiotherapy (RT) in early stage MZL [4]. A Surveillance,
Epidemiology and End Results (SEER)-Medicare database analysis of stage IE gastric MALT lymphoma showed that RT was
associated with lower risk of lymphoma-related death than
chemotherapy [5]. The available studies on this disease have not
consistently assessed the response to primary therapies, mostly
due to small patient numbers, a lack of homogenous patient cohorts and variable follow-up strategy [3, 4, 6–12]. Furthermore,
these studies find conflicting prognostic factors for disease relapse and survival.
In this study, we describe the response and long-term outcome
of early-stage disease following various initial therapies. We also
aim to find prognostic factors for relapse and survival.

Materials and methods
Patient selection
We carried out an IRB-approved retrospective analysis of the medical records of 487 consecutive patients treated at Memorial Sloan Kettering
Cancer Center who had biopsy-proven stage I or II extra-nodal MZL
diagnosed between January 1992 and September 2012. All patients had
pathologic confirmation of MZL diagnosis by a MSKCC hematopathologist. We collected information on clinical features, stage, diagnostic studies, performance status, International Prognostic Index [13] score,
treatments received, follow-up examinations, relapses or progression of
disease (PD), and salvage therapies for recurrences.

Initial workup
Staging workup followed institutional standards for the disease site as
well as NCCN guidelines. Work-up included an appropriate imaging
study [positron emission tomography (PET) scan, computed tomography (CT), or magnetic resonance imaging (MRI)] as well as complete
blood count and basic metabolic panel. All patients with gastric MZL
were diagnosed by esophagogastroduodenoscopy (EGD) inspection and
biopsy. Bone-marrow biopsy was carried out at physician discretion.

Treatment
Extra-nodal MZLs were treated with a relatively homogenous therapeutic
strategy. Treatment of early-stage extra-nodal MZL at our institution
constitutes primarily either radiotherapy or surgical resection. A cohort
of patients treated only with RT has been previously published [15].
Some patients are treated at physician discretion with systemic therapies
including cytotoxic chemotherapy or targeted immunotherapies, in particular rituximab. Gastric MZL patients are referred for RT if they have
H. pylori-independent disease (biopsy does not identify H. pylori) or fail
antibiotic therapy for H. pylori eradication based on repeat gastric biopsy.
Based on the clinical setting, such as skin MZL or patients who wish to
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delay treatment, a minority of patients are initially managed with antibiotics, topical steroids, or observation (active surveillance approach).

Follow-up
Patients were typically seen 1-4 months after completing treatment of initial response and toxicity assessment. Imaging studies were used to assess
response for most sites, with the exception of skin and orbit sites, where
principally clinical examination was used. For gastric MZL, EGD with biopsy was customarily carried out every 4-6 months for the first 2-3 years,
after which annual EGD was carried out.
Radiographic response was determined according to the International
Working Group response criteria [14] at time of first follow-up imaging
study; in some cases, we retrospectively ascertained clinical or radiographic response. Responses were categorized as one of the following:
complete response (CR), complete response uncertain (CRu), partial response (PR), stable disease (SD), and PD.
For all patients receiving treatment, a progression or relapse event
during follow-up was classified as any measurable, biopsy-proven, or
visible increase in existing disease; relapse in initial site after initial CR;
or the development of an entirely new site of MZL. For gastric MZL,
biopsy-proven recurrence was required to determine relapse. Disease
that transformed to large cell lymphoma was also considered a progression event.

Treatment technique
Patients who received RT were treated with either involved field RT
(IFRT) or involved site RT (ISRT) without intentional prophylactic treatment of regional nodes unless the nodal drainage fell within the involved
field, as previously reported [10]. Surgical resection involved removal of
all visible disease on imaging or clinical examination.

Statistical analysis
Endpoints of our study were overall survival (OS), relapse-free survival
(RFS), disease-specific death rate, relapse rate, and in-field failure rate
after RT. Follow-up began from treatment start date for all endpoints except in-field failure. For OS, patients were followed until date of death or
last contact, if still alive; for disease-specific death, death due to causes
unrelated to MZL was considered a competing risk event. For RFS, patients were followed until the date of progression, relapse in previous or
new site, death, or last follow-up; for the relapse endpoint, death without
relapse was a competing risk event. For in-field failure after RT, which
included patients that received RT any time after diagnosis, patients were
followed from end of RT until progression or recurrence within the irradiated site and death without in-field failure was a competing risk event.
Median OS and RFS were estimated by Kaplan–Meier methods.
Cumulative incidence rates of all other endpoints were estimated by competing risk methods.
We further estimated the cumulative incidence of first relapse at specific sites (local, regional, distant) after CR or CRu to initial treatment.
Patients were followed from the date of CR/CRu determination until first
relapse. Death without relapse was considered a competing risk event.
To identify prognostic factors associated with OS and relapse, we carried out multivariable analysis (MVA) using Cox regression and competing risk regression. For each endpoint, factors with a P < 0.2 by
univariate analysis (UVA) were assessed by MVA and backwards selection was used to reduce the model and retain only factors with P < 0.05.
To evaluate the association of relapse with OS, relapse was analyzed as a
time-dependent variable to account for biases related to different lengths
of waiting time between diagnosis and relapse. Age differences by disease
site were assessed with analysis of variance. Competing risks analysis was
carried out using package cmprsk in R version 2.11.1 (The R Foundation
for Statistical Computing). All other statistical analyses were carried out
in SAS version 9.2 (SAS Institute, Cary, NC).
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Results
Patient characteristics
Median follow-up was 4.7 years (range 0.01-21.3 years) overall
and 4.6 years among 415 survivors (range 0.01-21 years). Median
age at diagnosis was 60 years (range 9–92). A 57% of patients
were female (Table 1). Most patients (89%) had Ann Arbor stage
IE disease. Primary site of disease was the stomach in 32%, orbit
in 14%, lung in 12%, skin in 13%, parotid in 5%, thyroid in 2%,
and other in 22% (Table 1; supplementary Figure S1, available at
Annals of Oncology online). IPI score was zero or one (low risk) in
95% and two (low-intermediate risk) in 5%; 4% of patients had
B-symptoms at diagnosis. Age differed significantly between the
major categories of primary disease site (supplementary Table S1,
available at Annals of Oncology online), with parotid and skin
MZL presenting at younger ages.
For staging workup, 58% of patients had PET scan, 87% had
CT scan, and 49% had both PET and CT. EGD was carried out in
41% of patients and MRI was done in 18%. Bone-marrow biopsy
was carried out and was negative in 54% of patients; 45% of patients did not undergo bone marrow sampling.
Forty-five patients (9%) had a prior autoimmune disorder diagnosis, including Sjogren’s disease in 20 patients, Hashimoto’s thyroiditis in nine, rheumatoid arthritis in 11, systemic lupus
erythematosus in three, and inflammatory bowel disease in two patients. Helicobacter pylori infection was diagnosed in 44 patients
with gastric MZL. The majority of H. pylori-positive gastric patients (84%) received antibiotic therapy. Non-gastric patients were
not treated with antibiotics against H. pylori. Patients were referred
for radiotherapy if found to have persistent gastric MZL after completion of antibiotics and repeat endoscopy with biopsy.

Initial treatments
Treatments started shortly after diagnosis with a median interval
of 1.5 months. Radiotherapy was the most common initial treatment, given in 50% of patients (Tables 1 and 2). Surgical resection was the second most common therapy (30%), followed by
observation (8%), other treatments (6%: includes oral antibiotics
in 19 patients and topical corticosteroids in five), immunotherapy (4%), and systemic chemotherapy (2%). Observation was the
initial strategy in 39 patients representing various disease sites,
with the most common site being skin (44%) followed by orbit
(18%). Immunotherapy consisted of rituximab in 17 of 19 patients. Patients who received non-local therapies were not more
likely to have B-symptoms, nor did they have higher IPI score.
See supplementary results, available at Annals of Oncology online
for details about systemic therapy and RT, including toxicity.

Annals of Oncology
Table 1. Characteristics of early stage patients
Characteristic
Age
Gender

N 5 487
Median (range)

60 (9–92)

Female
Male

277 (57%)
210 (43%)

I
II

434 (89%)
53 (11%)

Stomach
Orbit
Lung
Skin
Head and neck
Thyroid
Other

155 (32%)
68 (14%)
60 (12%)
61 (13%)
26 (5%)
9 (2%)
108 (22%)

Unknown
Low risk (0–1 points)
Low-intermediate risk (2 points)

2 (0%)
461 (95%)
24 (5%)

Not present
Present
N/A

463 (95%)
18 (4%)
6 (1%)

Surgery
Chemotherapy
Radiation therapy
Chemotherapy and RTa
Immunotherapy
Observation
Other

144 (30%)
9 (2%)
244 (50%)
2 (0%)
19 (4%)
39 (8%)
30 (6%)

>1 site
1 site

37 (8%)
450 (92%)

Stage

Primary site at diagnosis

IPI risk group

B-symptoms at diagnosis

Initial treatment type

Sites at diagnosis

Bone marrow biopsy
Not done or N/A
Negative
Among patients receiving RT as initial treatment (N ¼ 246)b
RT dose
<3000
3000
>3000
Unknown dose

222 (46%)
265 (54%)

42 (17%)
157 (64%)
37 (15%)
10 (4%)

Percentages may not add up to 100 due to rounding.
Grouped with RT for analysis.
b
Includes ChemoRT as initial treatment.
IPI, International Prognostic Index; RT, radiotherapy.
a

Response rates
All 144 patients treated with surgery had complete resections and
therefore achieved CR. Among the 274 total patients receiving
curative initial treatments (RT, chemotherapy, or immunotherapy), 82% achieved CR, 4% achieved CRu, 6% achieved PR, 4%
had stable disease, and 1% experienced PD during treatment.
Response was not recorded in 2% of patients. Among the RTonly group, 89% achieved CR, 5% had CRu, 3% had PR, 1% had
SD, 1 patient had PD, and 2% had unknown response.
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Overall survival
Seventy-two patients died during the follow-up period. Median
OS was 15 years (95% CI 14.4–not reached). Five-year OS was
89% (95% CI 85%–92%), and 10-year OS was 73% (95% CI
65%–79%) (Figure 1A). Cause of death was MZL in six patients,
other cause in 44 patients, and uncertain in 22 patients.
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The 5- and 10-year cumulative incidences of disease-specific
death are 1.3% (95% CI 0.02%––2.6%) and 1.8% (95% CI
0.2%––3.3%), respectively (Figure 1B). Non-lymphoma causes
of death included second primary solid tumor malignancies (not
associated with treatment) in 22 patients, second primary hematologic malignancies in 6 patients, medical causes including
pneumonia in 6 patients, and car accident in one. Eight of the 22
patients with uncertain cause of death had experienced relapse at
some time before death, including two with transformed disease;
all eight were treated for their relapse. The median age at death
for these patients was 73 years.

Relapses and progression
One-hundred ninety-five patients experienced relapse or death
during the follow-up period, of which 151 patients relapsed (28
of whom died subsequently), and 44 patients died without a relapse. Median RFS was 8.1 years (95% CI 6.3–9.7 years). Fiveyear RFS was 60% (95% CI 55%––65%), and 10-year RFS was
42% (95% CI 35%––49%) (Figure 2A). For details of relapse locations and salvage therapies, refer to supplementary results and
Tables S3–S5, and Figure S2, available at Annals of Oncology
online.
The 5-year cumulative incidence of relapse for all patients was
33% (95% CI 28%–38%), with a 10-year incidence of 42% (95%
CI 36%–48%) (Figure 2B). Patients who experienced progression
or relapse during the follow-up period had higher risk of death
that was borderline significant (HR 1.60, P ¼ 0.06).
Table 2. Initial treatment types for each major MZL disease site
Initial treatment Stomach Orbit
N (%)
N (%)
Radiation therapy 122 (79)
Surgery
4 (3)
Chemotherapy
3 (2)
Immunotherapy
6 (4)
Observation
2 (1)
Other
18 (12)

Lung
N (%)

Skin
N (%)

Parotid Thyroid Other
N (%)
N (%)
N (%)

44 (65) 1 (2) 19 (31) 7 (27)
10 (15) 54 (90) 18 (30) 16 (62)
0
1 (2)
1 (2)
0
3 (4)
2 (3)
1 (2)
1 (4)
7 (10) 2 (3) 17 (28) 1 (4)
4 (6)
0
5 (8)
1 (4)

5 (56)
4 (44)
0
0
0
0

48 (44)
38 (35)
4 (4)
6 (6)
10 (9)
2 (2)

Percentages may not add up to 100 due to rounding.

Discussion
We present, to our knowledge, the largest report of early-stage
extra-nodal marginal zone lymphoma treatment and outcomes
in the literature. With a median follow-up of almost 5 years, our
study presents a comprehensive picture of the disease course of
extra-nodal MZL. Our study confirms that extra-nodal MZL disease control is excellent following local or systemic therapies and
disease-specific death is rare. For patients who achieve CR to
treatment, local relapse is uncommon; when relapse does occur,
as is the case in one-third of patients, the relapsed disease is almost always a non-transformed MZL emerging in an extra-nodal
site and can be treated successfully in the relapsed setting.
An important finding of our data is that, despite the ability of
systemic chemotherapy or rituximab to treat disseminated
microscopic disease, patients treated with these modalities were
not less likely to relapse. Given these results, we prefer to avoid
the toxicities of systemic therapy, and instead offer all patients
local therapy for this disease. We reserve systemic therapy for the
few patients who relapse and require a systemic approach. The
low radiation doses required for CR are associated with few serious complications [15].
We identify several factors associated with risk of relapse in
early-stage extra-nodal MZL, including primary disease site and
initial treatment type. Compared with gastric primaries, patients

B

Overall survival
1.0

1.0

0.8

0.8
Probability

Probability

A

In both UVA and MVA for relapse, primary disease site, initial
treatment type, and number of sites at diagnosis were significantly associated with relapse (Table 3; Figure 2C). Among treatment types, only “other” treatments, such as topical therapies or
antibiotics, were significantly associated with a greater risk of relapse than RT (HR 8.37, P < 0.001).
Among the 294 patients treated with RT either upfront or for a
relapse, 11 experienced failures within the radiation field. The 5and 10-year cumulative incidences of in-field failure after RT
were 2.4% (95% CI 0.5%–4%) and 4.7% (95% CI 0.8%–8.7%),
respectively.
Eleven patients (2%) experienced transformation of MZL to
pathologically confirmed large-cell lymphoma. Initial sites of disease were stomach (n ¼ 5), orbit (3), parotid (2), and breast (1).
Of these, two died of disease. Transformation occurred at the primary disease site in three patients, and in a regional or distant site
in eight patients.

0.6
0.4

N =487 (72 Deaths)
Median survival: 15 years, 95%CI
(14.4-Not achieved)
Median follow-up for survivors: 5 years

0.2

Cumulative incidence of
disease-specific deaths
N =487 (6 DOD)

0.6
0.4
0.2
0

0
0

5

10

15

Years since start of initial treatment

0

5

10

15

Years since start of initial treatment

Figure 1. (A) Overall survival. (B) Cumulative incidence of disease-speciﬁc deaths.
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Relapse-free survival

Cumulative incidence of relapse/progression

1.0

1.0

0.8

0.8

C

Cumulative incidence of
relapse by primary disease site
1.0

Stomach
Orbit
Lung
Skin
Parotid
Thyroid
Other

0.8

0.6
0.4
N =483 (195 RFS events)

0.2

Probability

Probability

Probability

N =483 (151 events)
0.6
0.4
0.2

0

5
10
Years since start of initial treatment

15

0.4
0.2

0

0

0.6

0
0

5
10
15
Years since start of initial treatment

0

15
5
10
Years since start of initial treatment

Figure 2. (A) Relapse-free survival. (B) Cumulative incidence of relapse for all patients. (C) Cumulative incidence of relapse by primary disease site.
Table 3. Competing risk regression analysis for association of factors with relapse/progression (N 5 483)a
Characteristic

Strata

Univariate
HR (95%CI)

Age (per 10 years)
Gender
Stage
Primary site at diagnosis

IPI risk group
B-symptomsa
Initial treatment

No. sites at diagnosis
Bone marrow biopsy carried out

Female
Male
I
II
Stomach
Orbit
Lung
Skin
H&N
Thyroid
Other
Low (0–1 points)
Low-intermediate risk (2 points)
Not present at diagnosis
Present
RT or ChemoRT
Surgery
Chemo or immunotherapy
Observation
Other
>1 site
1 site
No
Yes

1.01 (0.89, 1.15)
1.0
1.05 (0.76, 1.45)
1.0
1.5 (0.99, 2.29)
1.0
1.9 (1.13, 3.2)
1.81 (1.03, 3.17)
2.73 (1.6, 4.65)
2.6 (1.34, 5.05)
0.8 (0.22, 2.93)
1.91 (1.2, 3.06)
1.0
1.53 (0.73, 3.18)
1.0
1.08 (0.4, 2.91)
1.0
1.22 (0.83, 1.80)
2.27 (1.19, 4.31)
2.03 (1.19, 3.49)
8.27 (4.07, 17)
1.0
0.54 (0.34, 0.84)
1.0
0.76 (0.55, 1.04)

Multivariable
P-value

HR (95%CI)

P-value

1.0
2.01 (1.07, 3.78)
3.16 (1.5, 6.66)
2.99 (1.67, 5.35)
3.8 (1.92, 7.54)
1.23 (0.34, 4.41)
2.5 (1.51, 4.14)

<.001

1.0
0.69 (0.42, 1.14)
1.5 (0.73, 3.09)
1.24 (0.69, 2.24)
8.37 (4.39, 15.94)
1.0
0.58 (0.35, 0.97)

<.001

0.87
0.76
0.06
<0.001

0.26
0.88
<0.001

0.007

0.04

0.09

Variables with P-value <0.2 were selected for multivariable analysis and only variables with P-value < 0.05 were retained in the ﬁnal model.
Unknown relapse status not included.
HR, hazard ratio; IPI, International Prognostic Index, RT, radiotherapy.

a

with orbit, lung, skin, parotid, and other disease sites are significantly more likely to relapse or progress. These sites tend to represent (i) paired organs such as orbit or parotid, and (ii) organs where
only the involved site of disease, and not the whole organ, is locally
treated—such as the lung and skin. In contrast, RT for stomach
MZL involves treatment of the entire organ. This variation in treatment extent for different disease sites may explain higher relapse
rates between stomach and other sites. Our finding confirms similar
results from previous smaller studies [4, 12, 16–18]. The association
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of certain organ sites with higher risk of relapse may support closer
follow-up for those patients, with special attention to the remainder
of the involved organ or to its contralateral, paired structure.
We find that, compared with RT, patients receiving “other”
treatments, including antibiotics and corticosteroids, were significantly more likely to experience relapse while patients undergoing
surgery were not. Gastric, skin, or orbit sites are more likely to receive “other” therapies. Because these treatments do not address
the entire organ, patients will more likely have partial response and
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eventual relapse. Patients who were observed were highly selected,
and likely had minimal residual disease burden after biopsy before
embarking on “observation only” approach.
Recent analyses of population databases have identified improved
outcomes in patients receiving RT as initial treatment of an early
stage extra-nodal MZL. Ling et al. identified over 22 000 patients in
the NCDB with stage I-II extra-nodal and nodal MZL from 1998 to
2012 [4]. They found that RT utilization had decreased over time
with a corresponding increase in systemic therapy. Propensity-score
adjusted survival analysis found that RT was independently associated with improved OS (Hazard ratio 0.75). An analysis of 1134
cases of stage IE gastric MZL from the SEER-Medicare database
found that RT was associated with a better cause-specific survival
compared with those treated with chemotherapy [5].
Other groups have reported excellent outcomes of early-stage
extra-nodal MZL that are further supported by our study. A multicenter report [19] from the International Extra-nodal Lymphoma
Study Group (IELSG) reported on 102 patients receiving RT for gastric MZL. Ten-year freedom from treatment failure and overall survival were 88% and 70%, respectively. Princess Margaret Hospital
investigators identified 192 patients with stage IE-IIE MZL treated
with RT, 23 of whom also received chemotherapy [6, 11]. Ten-year
RFS was 68% and 10-year cause-specific survival was 98%. Thyroid
and stomach sites had >90% 10-year recurrence-free rates. A prospective phase II trial of RT in stage IEA MZL showed 3-year OS of
100% and local control of 97% [7]. Lastly, a study of stage IE orbital
MZL show >95% local control following RT [20]; 6 patients had a
contralateral orbital relapse and were salvaged with RT.
The limitation of our study is its retrospective nature. The nature
of treatments at a tertiary referral center such as ours does raise the
possibility of referral biases, which may explain the high number of
patients who received radiotherapy as primary treatment of gastric
MZL. Similarly, very few patients with gastric disease were treated
with surgery. Given the lack of a prospective study, our retrospective study presents a clear picture of the natural history of various
treatment strategies for early-stage extra-nodal MZL, one that can
inform treatment paradigms for future patients.
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